End Stage Renal Failure on Dialysis Clinical Trial
Official title:
Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2
Little is known about how some drugs affect inflammation or clotting factors in people receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they do in people not undergoing hemodialysis or whether they could increase the risk of heart problems. The purpose of the study is to measure certain chemicals in the blood and see how those chemicals may change during hemodialysis when certain drugs are given.
- Cardiovascular disease in the leading cause of death in patients with chronic kidney
disease undergoing hemodialysis.
- Traditional risk factors do not adequately predict cardiovascular morbidity and
mortality in patients with chronic kidney disease.
- Increased oxidative stress, inflammation and impaired fibrinolysis contribute to
cardiovascular risk in chronic kidney disease patients undergoing hemodialysis.
- Activation of the renin-angiotensin-aldosterone system(RAAS) may contribute to
oxidative stress and inflammation in individuals with chronic kidney disease
- Activation of the kallikrein-kinin system during hemodialysis may increase fibrinolysis
but may also contribute to inflammation in chronic kidney disease
- Despite data from clinical trials demonstrating that ARBs and ACE inhibitors decrease
cardiovascular mortality, delay progression to cardiovascular disease and decrease the
incidence of diabetes in the general population little is known about the impact of
these agents on cardiovascular morbidity and mortality in patients with end- stage
renal disease (ESRD) undergoing hemodialysis
- Angiotensin-converting enzyme(ACE) inhibitors and angiotensin receptor blockers (ARB)S
differ in their mechanisms of action and their effects on inflammatory biomarkers
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04103177 -
Physical Activity in Haemodialysis Patients: a Feasibility Study
|
N/A | |
Completed |
NCT01561118 -
DiaSport - Endurance-orientated Training Program With Children and Adolescents on Maintenance Hemodialysis
|
N/A | |
Withdrawn |
NCT03645720 -
The Prognosis of Graft Using Plastic Cannula in Hemodialysis
|
N/A | |
Active, not recruiting |
NCT02598635 -
Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis
|
Phase 4 | |
Terminated |
NCT01643733 -
Study on Fistuloplasty Using Flow Measurement Guidance
|
N/A | |
Not yet recruiting |
NCT03169400 -
Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)
|
N/A | |
Completed |
NCT02439697 -
A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients
|
N/A | |
Completed |
NCT02063490 -
Nurse-led Intervention to Improve Phosphate Binder Adherence
|
N/A | |
Completed |
NCT04106310 -
Theranova vs High-flux HD Comparison
|
N/A | |
Recruiting |
NCT06056102 -
CAR-T Cell Therapy for Desensitization in Kidney Transplantation
|
Phase 1 | |
Completed |
NCT04698512 -
MAgicTouchâ„¢ Intervention Leap for Dialysis Access (MATILDA) Trial
|
||
Completed |
NCT02819011 -
OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
|
Phase 2 | |
Completed |
NCT02484118 -
Hemodialysis Blood Flow and Urea Clearance
|
N/A | |
Enrolling by invitation |
NCT01641757 -
Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy,
|
Phase 2 | |
Completed |
NCT03172039 -
Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit
|
N/A | |
Completed |
NCT03897231 -
Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis
|
||
Withdrawn |
NCT03145662 -
High Pressure Balloon vs Cutting Balloon
|
N/A | |
Completed |
NCT02621918 -
The Effects of Exercise in End-stage Renal Disease Patients Undergoing Hemodialysis
|
N/A | |
Completed |
NCT01356615 -
Low Molecular Weight Heparin for Hemodialysis Anticoagulation
|
N/A | |
Terminated |
NCT01033357 -
Safety Study of the Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
|
N/A |